Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition

Cancer Letters

Volumn 348, Issue 1-2, 2014, Pages 135-145

  Jing, Yifeng ^a   Cui, Di ^a   Guo, Wenhuan ^b   Jiang, Juntao ^a   Jiang, Bo ^a   Lu, Youyi ^a   Zhao, Wei ^a   Wang, Xiaohai ^a   Jiang, Qi ^a   Han, Bangmin ^a   Xia, Shujie ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Androgen receptor; Bladder cancer; Epithelial mesenchymal transition; Slug

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BETA CATENIN; TRANSCRIPTION FACTOR SLUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BLADDER CANCER; CANCER CELL; CELL NUCLEUS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT; UPREGULATION;

ANDROGEN RECEPTOR; BLADDER CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; SLUG;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BETA CATENIN; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRANSFECTION; URINARY BLADDER NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84900511675     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.018     Document Type: Article

References (45)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
2. Madersbacher S., Hochreiter W., Burkhard F., Thalmann G.N., Danuser H., Markwalder R., Studer U.E. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J. Clin. Oncol. 2003, 21:690-696.
3. Shariat S.F., Karakiewicz P.I., Palapattu G.S., Lotan Y., Rogers C.G., Amiel G.E., Vazina A., Gupta A., Bastian P.J., Sagalowsky A.I., Schoenberg M.P., Lerner S.P. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J. Urol. 2006, 176:2414-2422. (discussion 2422).
4. Hartge P., Harvey E.B., Linehan W.M., Silverman D.T., Sullivan J.W., Hoover R.N., Fraumeni J.F. Unexplained excess risk of bladder cancer in men. J. Natl. Cancer Inst 1990, 82:1636-1640.
5. Hemelt M., Yamamoto H., Cheng K.K., Zeegers M.P.A. The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int. J. Cancer 2009, 124:412-419.
6. Miyamoto H., Yang Z., Chen Y.-T., Ishiguro H., Uemura H., Kubota Y., Nagashima Y., Chang Y.-J., Hu Y.-C., Tsai M.-Y., Yeh S., Messing E.M., Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. J. Natl. Cancer Inst. 2007, 99:558-568.
7. Kauffman E.C., Robinson B.D., Downes M.J., Powell L.G., Lee M.M., Scherr D.S., Gudas L.J., Mongan N.P. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 2011, 50:931-944.
8. Wu J.-T., Han B.-M., Yu S.-Q., Wang H.-P., Xia S.-J. Androgen receptor is a potential therapeutic target for bladder cancer. Urology 2010, 75:820-827.
9. Zheng Y., Izumi K., Yao J.L., Miyamoto H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr. Relat. Cancer 2011, 18:451-464.
10. Boorjian S., Ugras S., Mongan N.P., Gudas L.J., You X., Tickoo S.K., Scherr D.S. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004, 64:383-388.
11. Tuygun C., Kankaya D., Imamoglu A., Sertcelik A., Zengin K., Oktay M., Sertcelik N. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol. Oncol. 2011, 29:43-51.
12. Miyamoto H., Yao J.L., Chaux A., Zheng Y., Hsu I., Izumi K., Chang C., Messing E.M., Netto G.J., Yeh S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012, 109:1716-1726.
13. Zhuang Y.H., Bläuer M., Tammela T., Tuohimaa P. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 1997, 30:556-562.
14. Birtle A.J., Freeman A., Munson P. The androgen receptor revisited in urothelial carcinoma. Histopathology 2004, 45:98-99.
15. Mir C., Shariat S.F., van der Kwast T.H., Ashfaq R., Lotan Y., Evans A., Skeldon S., Hanna S., Vajpeyi R., Kuk C., Alkhateeb S., Morote J., van Rhijn B.W.G., Bostrom P., Yao J., Miyamoto H., Jewett M., Fleshner N., Messing E., Zlotta A.R. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011, 108:24-30.
16. Shook D., Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech. Dev. 2003, 120:1351-1383.
17. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796:75-90.
18. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
19. Baumgart E., Cohen M.S., Silva Neto B., Jacobs M.A., Wotkowicz C., Rieger-Christ K.M., Biolo A., Zeheb R., Loda M., Libertino J.A., Summerhayes I.C. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin. Cancer Res. 2007, 13:1685-1694.
20. Fondrevelle M.E., Kantelip B., Reiter R.E., Chopin D.K., Thiery J.P., Monnien F., Bittard H., Wallerand H. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol. Oncol. 2009, 27:268-276.
21. Schulte J., Weidig M., Balzer P., Richter P., Franz M., Junker K., Gajda M., Friedrich K., Wunderlich H., Östman A., Petersen I., Berndt A. Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells. Histochem. Cell Biol. 2012, 138:847-860.
22. Sayan A.E., Griffiths T.R., Pal R., Browne G.J., Ruddick A., Yagci T., Edwards R., Mayer N.J., Qazi H., Goyal S., Fernandez S., Straatman K., Jones G.D.D., Bowman K.J., Colquhoun A., Mellon J.K., Kriajevska M., Tulchinsky E. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc. Natl. Acad. Sci. USA 2009, 106:14884-14889.
23. Liu Y.-N., Liu Y., Lee H.-J., Hsu Y.-H., Chen J.-H. Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol. Cell Biol. 2008, 28:7096-7108.
24. Zhu M.-L., Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2010, 24:769-777.
25. Wu K., Gore C., Yang L., Fazli L., Gleave M., Pong R.-C., Xiao G., Zhang L., Yun E.-J., Tseng S.-F., Kapur P., He D., Hsieh J.-T. Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Mol. Endocrinol. 2012, 26:1496-1507.
26. Montironi R., Lopez-Beltran A. The WHO classification of bladder tumors: a summary and commentary. Int. J. Surg. Pathol. 2004, 13(2005):143-153.
27. Jiang B., Li E.-H., Lu Y.-Y., Jiang Q., Cui D., Jing Y.-F., Xia S.-J. Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer. Urology 2012, 80. 484.e489-415.
28. Wu Z.-Q., Li X.-Y., Hu C.Y., Ford M., Kleer C.G., Weiss S.J. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc. Natl. Acad. Sci. USA 2012, 109:16654-16659.
29. Lascombe I., Clairotte A., Fauconnet S., Bernardini S., Wallerand H., Kantelip B., Bittard H. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin. Cancer Res. 2006, 12:2780-2787.
30. Hu X., Ruan Y., Cheng F., Yu W., Zhang X., Larré S. P130Cas E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int. J. Urol. 2011, 18:630-637.
31. Tharakan S.T., Inamoto T., Sung B., Aggarwal B.B., Kamat A.M. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem. Pharmacol. 2010, 79:218-228.
32. Chen L.-M., Verity N.J., Chai K.X. Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT). BMC Cancer 2009, 9:377.
33. Heuberger J., Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb. Perspect. Biol. 2010, 2:a002915.
34. Lambertini E., Franceschetti T., Torreggiani E., Penolazzi L., Pastore A., Pelucchi S., Gambari R., Piva R. SLUG: a new target of lymphoid enhancer factor-1 in human osteoblasts. BMC Mol. Biol. 2010, 11:13.
35. McConkey D.J., Choi W., Marquis L., Martin F., Williams M.B., Shah J., Svatek R., Das A., Adam L., Kamat A., Siefker-Radtke A., Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009, 28:335-344.
36. Adam L., Zhong M., Choi W., Qi W., Nicoloso M., Arora A., Calin G., Wang H., Siefker-Radtke A., McConkey D., Bar-Eli M., Dinney C. MiR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15:5060-5072.
37. Hajra K.M., Chen D.Y.-S., Fearon E.R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002, 62:1613-1618.
38. Pérez-Mancera P.A., González-Herrero I., Pérez-Caro M., Gutiérrez-Cianca N., Flores T., Gutiérrez-Adán A., Pintado B., Sánchez-Martín M., Sánchez-García I. SLUG in cancer development. Oncogene 2005, 24:3073-3082.
39. Wu K., Zeng J., Zhou J., Fan J., Chen Y., Wang Z., Zhang T., Wang X., He D. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development. Urol. Oncol. 2013, 31:1751-1760.
40. Ahmad I., Morton J.P., Singh L.B., Radulescu S.M., Ridgway R.A., Patel S., Woodgett J., Winton D.J., Taketo M.M., Wu X.R., Leung H.Y., Sansom O.J. Beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 2011, 30:178-189.
41. Kashibuchi K., Tomita K., Schalken J.A., Kume H., Yamaguchi T., Muto S., Horie S., Kitamura T. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur. Urol. 2006, 49:839-845. (discussion 845).
42. Terry S., Yang X., Chen M.-W., Vacherot F., Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J. Cell Biochem. 2006, 99:402-410.
43. Li Y., Zheng Y., Izumi K., Ishiguro H., Ye B., Li F., Miyamoto H. Androgen activates β-catenin signaling in bladder cancer cells. Endocr. Relat. Cancer 2013, 20:293-304.
44. Stemmer V., de Craene B., Berx G., Behrens J. Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene 2008, 27:5075-5080.
45. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 2002, 20:3001-3015.